Axicabtagene Ciloleucel (Yescarta®) is now publicly funded in Australia for relapsed or refractory DLBCL, PMBCL, TFL and HGBCL
Kite, A Gilead company, have announced that its CAR-T cell therapy, axicabtagene ciloleucel (Yescarta®), is now publicly funded and available for the treatment of patients with relapsed or refractory CD-19 […]